|
Adlyfe Appoints Gretchen L. Schieber as Vice President of Diagnostic Development
ROCKVILLE, MARYLAND, September 24, 2007 -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today that it has appointed Gretchen L. Schieber, PhD, MBA as Vice President of Diagnostic Development. Dr. Schieber will be responsible for guiding the new product development and commercialization of Adlyfe's novel diagnostics and will report directly to the Chief Executive Officer.
Dr. Schieber brings twenty years of experience in new product development and commercialization in biotechnology and medical diagnostics companies; an extensive record of success in new product definition, development, and commercialization across multiple companies, product areas, technologies, and formats; and a solid background in business and cell biology and biochemistry. Dr. Schieber most recently served at Affymetrix for seven years, where she held the position of Associate Director of Product R&D Operations. Before that, Dr. Schieber was a Project Manager at Dade Behring.
Alan Rudolph, President and CEO of Adlyfe, said, "As the Company seeks to bring a truly novel Alzheimer's diagnostic to the market, we are pleased to bring Gretchen on board. Her combined business and science background will serve to aid the company in bringing this technology into the clinic."
Gretchen Schieber commented, "I am looking forward to executing in my new role at Adlyfe and to joining its first-rate development team. I believe that my experience in new product definition, development, and commercialization will serve well in support of this promising diagnostic technology."
About Adlyfe
Adlyfe Inc. was established early in 2003 to develop novel technologies
for blood testing for early targets of amyloid diseases. Adlyfe is
developing a novel test for the detection and amplification of amyloid
proteins as early biomarkers of fatal brain and amyloid diseases such as
Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease,
Huntington's disease, systemic amyloidosis, diabetes and other diseases.
The Company's novel technology is based on the synthesis of small
peptide, or Pronucleon(TM) ligands, that are amino acid sequence matched to
target amyloids of interest. Ligand sequences are selected based on regions
of the target protein known to undergo conformational changes (structural
changes in shape) associated with amyloid aggregation (and eventual amyloid
plaque formation). These aggregates are associated with disease state
progression in a number of brain-wasting and amyloid diseases.
Adlyfe, a privately-held corporation, was initially funded by the
Defense Advanced Research Projects Agency (DARPA), the U.S. Army Medical
Research and Materiel Command, the National Heart, Lung and Blood
Institute, and Britain's Department for Environment, Food and Rural
Affairs. More recently, Adlyfe raised additional funding with venture
capital firms Canaan Venture Partners and Burrill Associates.
For More Information
Media:
Janine McCargo
1-646-536-7033
jmccargo@theruthgroup.com
|
